Abstract
The 2´3´-dialdehyde of ATP or oxidized ATP (oATP) is a compound known for specifically making covalent bonds with the nucleotide-binding site of several ATP-binding enzymes and receptors. We investigated the effects of oATP and other oxidized purines on HIV-1 infection and we found that this compound inhibits HIV-1 and SIV infection by blocking early steps of virus replication. oATP, oxidized ADP (oADP), and oxidized Adenosine (oADO) impact the natural activity of endogenous reverse transcriptase enzyme (RT) in cell free virus particles and are able to inhibit viral replication in different cell types when added to the cell cultures either before or after infection. We used UFLC-UV to show that both oADO and oATP can be detected in the cell after being added in the extracellular medium. oATP also suppresses RT activity and replication of the HIV-1 resistant variants M184V and T215Y. We conclude that oATP, oADP and oADO display anti HIV-1 activity that is at in least in part due to inhibitory activity on HIV-1 RT.
Keywords: HIV-1, macrophage, oxidized adenosine, oxidized ADP, oxidized ATP, reverse transcriptase.
Current HIV Research
Title:2´,3´-Dialdehyde of ATP, ADP, and Adenosine Inhibit HIV-1 Reverse Transcriptase and HIV-1 Replication
Volume: 12 Issue: 5
Author(s): Julieta Schachter, Ana Luiza Chaves Valadao, Renato Santana Aguiar, Victor Barreto-de-Souza, Atila Duque Rossi, Pablo Ricardo Arantes, Hugo Verli, Paula Gabriela Quintana, Norton Heise, Amilcar Tanuri, Dumith Chequer Bou-Habib and Pedro Muanis Persechini
Affiliation:
Keywords: HIV-1, macrophage, oxidized adenosine, oxidized ADP, oxidized ATP, reverse transcriptase.
Abstract: The 2´3´-dialdehyde of ATP or oxidized ATP (oATP) is a compound known for specifically making covalent bonds with the nucleotide-binding site of several ATP-binding enzymes and receptors. We investigated the effects of oATP and other oxidized purines on HIV-1 infection and we found that this compound inhibits HIV-1 and SIV infection by blocking early steps of virus replication. oATP, oxidized ADP (oADP), and oxidized Adenosine (oADO) impact the natural activity of endogenous reverse transcriptase enzyme (RT) in cell free virus particles and are able to inhibit viral replication in different cell types when added to the cell cultures either before or after infection. We used UFLC-UV to show that both oADO and oATP can be detected in the cell after being added in the extracellular medium. oATP also suppresses RT activity and replication of the HIV-1 resistant variants M184V and T215Y. We conclude that oATP, oADP and oADO display anti HIV-1 activity that is at in least in part due to inhibitory activity on HIV-1 RT.
Export Options
About this article
Cite this article as:
Schachter Julieta, Valadao Luiza Chaves Ana, Aguiar Santana Renato, Barreto-de-Souza Victor, Rossi Duque Atila, Arantes Ricardo Pablo, Verli Hugo, Quintana Gabriela Paula, Heise Norton, Tanuri Amilcar, Bou-Habib Chequer Dumith and Persechini Muanis Pedro, 2´,3´-Dialdehyde of ATP, ADP, and Adenosine Inhibit HIV-1 Reverse Transcriptase and HIV-1 Replication, Current HIV Research 2014; 12 (5) . https://dx.doi.org/10.2174/1570162X12666140826105824
DOI https://dx.doi.org/10.2174/1570162X12666140826105824 |
Print ISSN 1570-162X |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4251 |
Call for Papers in Thematic Issues
Management of HIV: Management of HIV: old challenges and new needs
The aim of this thematic issue is to provide the most recent updates regarding the effective management of HIV infection. Antiretroviral therapy (ART) has significantly decreased HIV-related mortality, leading to an enhancement in the quality of life and life expectancy for people living with HIV (PLWH). Despite the numerous advancements ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Flavopiridol, the First Cyclin-Dependent Kinase Inhibitor: Recent Advances in Combination Chemotherapy
Mini-Reviews in Medicinal Chemistry Editorial [Hot Topic: Nongenomic Effects of Thyroid Hormones in Central Nervous System and Skeletal Muscle (Guest Editor: Sandra Incerpi)]
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Spectrum of Radiopharmaceuticals in Nuclear Oncology
Current Cancer Drug Targets Na+-H+ Exchanger, pH Regulation and Cancer
Recent Patents on Anti-Cancer Drug Discovery Graphene and Graphene Oxide as a Docking Station for Modern Drug Delivery System
Current Drug Delivery 5-HT5 Receptors
Current Drug Targets - CNS & Neurological Disorders Melatonin and Aromatase in Breast Cancer
Clinical Cancer Drugs High Expression of MYL9 Indicates Poor Clinical Prognosis of Epithelial Ovarian Cancer
Recent Patents on Anti-Cancer Drug Discovery Updates of mTOR Inhibitors
Anti-Cancer Agents in Medicinal Chemistry Anti-cancer and Anti-angiogenic Properties of Various Natural Pentacyclic Tri-terpenoids and Some of their Chemical Derivatives
Current Organic Chemistry Hepatocyte Growth Factor Signaling in Cancer Metastasis
Current Signal Transduction Therapy The Role of Phenolic Compounds in the Fight against Cancer – A Review
Anti-Cancer Agents in Medicinal Chemistry Targeting Telomerase for Cancer Therapy
Current Cancer Therapy Reviews DLEU2: A Meaningful Long Noncoding RNA in Oncogenesis
Current Pharmaceutical Design MicroRNAs in Cancer Therapy: From Bench to Bedside
Current Cancer Therapy Reviews Context-dependent Action of Transforming Growth Factor β Family Members on Normal and Cancer Stem Cells
Current Pharmaceutical Design PET Tracers Based on 86Y
Current Radiopharmaceuticals Brain Tumor Causes, Symptoms, Diagnosis and Radiotherapy Treatment
Current Medical Imaging Engineered Liposomes for Drug Delivery and Biomedical Imaging
Recent Patents on Nanomedicine Anticancer Metallotherapeutics in Preclinical Development
Current Medicinal Chemistry